Breaking News

Tuesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
GRFS Grifols $22.76 -0.37 (-1.60%) 08:27 06/19/18 06/19 08:27 06/19/18 08:27 Hot Stocks	Grifols receives FDA approval for two blood screening assays » Grifols announced that it… Grifols announced that it has received approval from the FDA for two blood screening assays: Procleix Ultrio Elite and Procleix WNV. Procleix Ultrio Elite is an assay that allows for increased blood safety by screening and delivering simultaneous results for human immunodeficiency virus type 1, or HIV-1, hepatitis C virus, or HCV, and hepatitis B virus (HBV) as well as detecting HIV type 2 (HIV-2). The Procleix Ultrio Elite assay can be used to test pools of plasma composed of up to 96 individual donations from donors of source plasma. Procleix WNV assay is a highly sensitive, qualitative in vitro nucleic acid assay for the detection of West Nile virus RNA in plasma and serum of human blood donors. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
GRFS Grifols $24.10 -0.605 (-2.45%) , ARGX Argenx $98.39 -1.96 (-1.95%) 06:36 06/14/18 06/14 06:36 06/14/18 06:36 Downgrade	Grifols, Argenx rating change at JPMorgan » Grifols downgraded to… Grifols downgraded to Neutral ahead of competitor data at JPMorgan. JPMorgan analyst James Gordon last night downgraded Grifols to Neutral from Overweight and lowered his price target for the shares to $25.50 from $26.30. With 5% downside to consensus expectations in 2019 and 2020, the shares now look fully valued, Gordon tells investors in a research note. Further, the analyst sees competitor clinical data from Argenx (ARGX) and UCB in the second half of 2018 potentially raising questions as to the long-term sustainability of the auto-immune element of Grifols' immuno-globulin franchise. GRFS Grifols $24.10 -0.605 (-2.45%) ARGX Argenx $98.39 -1.96 (-1.95%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Jun
GRFS Grifols $24.10 -0.605 (-2.45%) 20:43 06/13/18 06/13 20:43 06/13/18 20:43 Downgrade	Grifols rating change at JPMorgan » Grifols downgraded to… Grifols downgraded to Neutral from Overweight at JPMorgan. JPMorgan analyst James Gordon downgraded Grifols to Neutral with an unchanged price target of EUR 21.50. The analyst views the valuation as full at current share levels. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $21.83 -0.32 (-1.44%) 07:38 06/01/18 06/01 07:38 06/01/18 07:38 Initiation	Grifols initiated at Barclays » Grifols initiated with an… Grifols initiated with an Overweight at Barclays. Barclays analyst Emily Field started Grifols with an Overweight rating and EUR 29 price target. The analyst views the company as the global leader in intravenous immunoglobulin therapy and thinks its investments "are about to pay off." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
GRFS Grifols $22.93 0.78 (3.52%) 08:08 05/14/18 05/14 08:08 05/14/18 08:08 Hot Stocks	Grifols expands blood typing solutions portfolio in the U.S. » Grifols announced the… Grifols announced the expansion of its blood typing solutions portfolio in the U.S. with the addition of antisera reagents. The U.S. FDA recently granted licensing approval for Grifols to commercialize a range of antisera reagents designed for routine and complex immunohematology testing. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
GRFS Grifols $21.53 -0.23 (-1.06%) 08:09 03/14/18 03/14 08:09 03/14/18 08:09 Upgrade	Grifols rating change at HSBC » Grifols upgraded to Hold… Grifols upgraded to Hold from Reduce at HSBC 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $22.90 -0.76 (-3.21%) 09:48 02/06/18 02/06 09:48 02/06/18 09:48 Hot Stocks	Grifols' HyperRAB 300 IU/mL receives FDA approval » Grifols has received… Grifols has received approval from the U.S. FDA for a new higher potency formulation of its HyperRAB rabies immune globulin for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, and for patients, the potential for fewer injections by significantly reducing the volume of medication administered in each dose. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
DE Deere $147.68 2.43 (1.67%) , SAN Banco Santander $6.62 0.155 (2.40%) … 10:01 11/24/17 11/24 10:01 11/24/17 10:01 Recommendations	On The Fly: Top five analyst actions » Catch up on today's… Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Deere (DE), upgraded to Buy from Hold at Deutsche Bank with analyst Nicole DeBlase saying positive earnings revisions should drive share outperformance from here. 2. Santander (SAN), upgraded to Buy from Neutral at Goldman Sachs. 3. Tim Participacoes (TSU), upgraded to Outperform from Market Perform at Itau BBA. 4. Grifols (GRFS), downgraded to Market Perform from Outperform at BBVA . 5. ZTO Express (ZTO), downgraded to Neutral from Buy at UBS with analyst Eric Lin citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. DE Deere $147.68 2.43 (1.67%) SAN Banco Santander $6.62 0.155 (2.40%) TSU Tim Participacoes $19.28 0.53 (2.83%) GRFS Grifols $23.04 -0.13 (-0.56%) ZTO ZTO Express $16.17 -0.84 (-4.94%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Nov
GRFS Grifols $23.04 -0.13 (-0.56%) 09:33 11/24/17 11/24 09:33 11/24/17 09:33 Downgrade	Grifols rating change at BBVA » Grifols downgraded to… Grifols downgraded to Market Perform from Outperform at BBVA 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $22.45 0.91 (4.22%) 05:58 10/31/17 10/31 05:58 10/31/17 05:58 Initiation	Grifols initiated at Citi » Grifols initiated with a… Grifols initiated with a Buy at Citi. Citi analyst Peter Verdult started Grifols with a Buy rating and EUR 30 price target. The analyst likes the company's recurring growth and rising margin outlook. His analysis suggests the shares are discounting a 10-15 year revenue growth expectation less than 5%. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial